Lightnews — Scholar-powered news

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87

Jame Abraham, MD, FACP @jameabraham.bsky.social · Sep 8

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87 www.nytimes.com/2025/09/07/s...

www.nytimes.com

4

Jame Abraham, MD, FACP @jameabraham.bsky.social · Sep 6

www.fiercebiotech.com/biotech/bion...

BioNTech's HER2 ADC beats Roche's Kadcyla in phase 3 breast cancer trial

BioNTech’s HER2 antibody-drug conjugate has beaten< | BioNTech’s HER2 antibody-drug conjugate has beaten Roche’s Kadcyla in a phase 3 breast cancer trial, positioning the company’s partner Duality Bio...

www.fiercebiotech.com

Jame Abraham, MD, FACP @jameabraham.bsky.social · Sep 6

It is Bike VeloSano weekend in #cleveland Thank you for coming together to raise money for cancer research @clevelandclinic.bsky.social ! Science and research saves lives !!

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with a...

Jame Abraham, MD, FACP @jameabraham.bsky.social · Aug 14

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy - The Lancet www.thelancet.com/journals/lan...

Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter despite substantial non-adherence. Longer follow-up would have been needed to help assess directly a...

www.thelancet.com

1 2

Jame Abraham, MD, FACP @jameabraham.bsky.social · Aug 13

ascopubs.org/doi/10.1200/... @ascocancer.bsky.social

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents | JCO Oncology Practice

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases that are prognostically stratified into lower-risk (LR-MDS) and higher-risk MDS on the basis of the International Prognostic Scori...

ascopubs.org

1 3

Jame Abraham, MD, FACP @jameabraham.bsky.social · Aug 9

We are excited to welcome Dr. Santhosh Rao as the Medical Director of the HemOnc team @ClevelandClinic Akron General! In addition to general oncology - he will be focusing on building a Genito Urinary Medical Oncology Program in @ClevelandClinic Southern Market

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jul 23

Pleaase join me in congratulating Nancy Musoke M.D, third year HemOnc Fellow Cleveland Clinic the reciepient of CLL Society’s 2025 Integrative Medicine Award. "Curcumin, Exercise and Placebo Effects on CLL / SLL Progression and Immune Function

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jul 14

Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates | JCO Oncology Practice ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jul 12

Outstanding talk on AI in healthcare by @neilmehtamd.medsky.social @clevelandclinic.bsky.social Artificial intelligence summit!

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 21

Wonderful to be part of one of the best cancer programs in the country as per @newsweek.com rankings.newsweek.com/americas-bes... @clevelandclinic.bsky.social

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 18

My conversations with Dr. Grobmyer of @clevelandclinic.bsky.social @ascopost.bsky.social ascopost.com/news/june-20...

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 9

Congratulations to the outstanding group of fellows graduating from @clevelandclinic.bsky.social Hematology and Medical Oncology Department in 2025! We are so proud of them and wish them all the best !!

meetings.asco.org/abstracts-pr...

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 2

Program Guide – ASCO Meeting Program Guide

meetings.asco.org

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 2

www.nejm.org/doi/full/10....

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | NEJM

Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | NEJM

1 4

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 1

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer @nejm.org @ascocancer.bsky.social @clevelandclinic.bsky.social

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 1

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer....

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jun 1

Wonderful to be part of the editorial board members of @ascopost.bsky.social ! #1 oncology news paper in the world ! Voice of @ascocancer.bsky.social

www.nejm.org/doi/full/10.... @oncoalert.bsky.social

Jame Abraham, MD, FACP @jameabraham.bsky.social · May 31

Thank you @theaacr.bsky.social for your leadership in advocating for cancer research! @ascocancer.bsky.social

1 6

Jame Abraham, MD, FACP @jameabraham.bsky.social · May 31

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer | NEJM

In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus...

www.nejm.org/doi/full/10.... @oncoalert.bsky.social

1 1

Jame Abraham, MD, FACP @jameabraham.bsky.social · May 31

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer | NEJM

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system. In this phase 3, open-label, randomized tria...

Jame Abraham, MD, FACP @jameabraham.bsky.social · May 30

Looking forward to seeing you at @ascocancer.bsky.social 2025 meeting - please visit @clevelandclinic.bsky.social booth

3

Jame Abraham, MD, FACP @jameabraham.bsky.social · May 18

We are looking for exceptional doctors to join our HemOnc team - Ohio/ Florida - if you are attending @ascocancer.bsky.social meeting please reach out jobs.clevelandclinic.org/job/16715724...